Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Urogynecology Journal
Erschienen in: International Urogynecology Journal 4/2015

01.04.2015 | Review Article

Pharmacological treatment of pure stress urinary incontinence: a narrative review

verfasst von: Mariam A. Malallah, Tariq F. Al-Shaiji

Erschienen in: International Urogynecology Journal | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

Treatment escalation from conservative directly to surgical in the management of pure stress urinary incontinence (SUI) reveals a gap for effective pharmacological treatments. The introduction of a drug therapy would fill this gap and widen the treatment options. Nevertheless, various pharmaceutical agents have been used off-label and are being investigated and becoming more widely available. In this review, we examined the latest published data regarding pharmacotherapy used in the treatment of SUI.

Methods

We performed a literature review to evaluate the relevant studies pertaining to any pharmacotherapy used in the management of SUI, examining the English language literature.

Results

Currently, no drug exists that is approved by the food and drug administration for the management of SUI. A few oral pharmacological agents are occasionally used off-label. Lack of proven efficacy and high incidence of bothersome side effects of these agents limit their use. Duloxetine, a serotonin norepinephrine reuptake inhibitor, represents a major therapeutic advance for the treatment of SUI based on findings from a number of controlled clinical trials.

Conclusions

Several pharmacological agents have been used off-label and investigated for safety and efficacy, but none has demonstrated sufficient effectiveness to receive widespread verification for its use in the treatment of SUI.
Literatur
1.
Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn 21:167–178CrossRefPubMed
2.
Haylen BT, de Ridder D, Freeman RM et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J J21:5–26CrossRef
3.
Hannestad YS, Rortveit G, Sandvik H et al (2000) A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. J Clin Epidemiol 53:1150–1157CrossRefPubMed
4.
Hunskaar S, Lose G, Sykes D et al (2004) The prevalence of urinary incontinence in women in four European countries. BJU Int 93:324–330CrossRefPubMed
5.
Iosif MD, Batra S, Ef A et al (1981) Oestrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol 141:817–820PubMed
6.
Padmanabhan P, Dmochowski R (2014) Urinary incontinence in women: a comprehensive review of the pathophysiology, diagnosis and treatment. Minerva Ginecol 66:469–478PubMed
7.
Wilson L, Brown JS, Shin GP et al (2001) Annual direct cost of urinary incontinence. Obstet Gynecol 98:398–406CrossRefPubMed
8.
Wilson P, Bo K, Bourcier A et al (1999) Conservative treatment in women. In: Cardozo L, Abrams P, Khoury G, Wein A (eds) Incontinence. Proceedings from the Second International Consultation on Incontinence. Health Publications, Plymouth, pp 579–634
9.
Hay-Smith EJ, Bo K, Berghmans LCM et al (2001) Pelvic floor muscle training for urinary incontinence in women. Cochrane Database Syst Rev 1:CD001407PubMed
10.
Robinson D, Anders K, Cardozo L et al (2003) What do women want?: interpretation of the concept of cure. J Pelvic Med Surg 9:273–277CrossRef
11.
Leach G, Dmochowski RR, Appell RA et al (1997) Female stress urinary incontinence clinical guidelines panel summary report on surgical management of female stress urinary incontinence. The American Urological Association. J Urol 158:875–880CrossRefPubMed
12.
DeLancey JOL (1997) The pathophysiology of stress urinary incontinence in women and its implications for surgical treatment. World J Urol 15(5):268–274CrossRefPubMed
13.
Henriksson L, Anderson KE, Ulmsten U (1979) The urethral pressure profiles in continent and stress incontinent women. Scand J Urol Nephrol 13:5–10CrossRef
14.
Hilton P, Stanton SL (1983) Urethral pressure measurement by microtransducer: the results in symptom-free women and in those with genuine stress incontinence. Br J Obstet Gynaecol 90:919–933CrossRefPubMed
15.
Anderson KE, Appell R, Cardozo L et al (2005) Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A (eds) Incontinence: 3rd international consultation on incontinence. Health Publications, Plymouth, pp 809–854
16.
Iosif CS, Bekassy Z (1984) Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand 63:257–260CrossRefPubMed
17.
18.
19.
Moerher B, Hextall A, Jackson S (2003) Oestrogens for urinary incontinence in women. Cochrane Database Syst Rev 2:CD001405
20.
Hextall A (2002) Oestrogens and lower urinary tract functions. Maturitas 36:83–87CrossRef
21.
Fantl JA, Bump RC, Robinson D et al (1996) Efficacy of oestrogen supplementation in the treatment of urinary incontinence. Obstet Gynaecol 88:745–749CrossRef
22.
Jackson S, Shepherd A, Brookes S et al (1999) The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind, placebo controlled trial. Br J Obstet Gynaecol 106:711–718CrossRefPubMed
23.
Grady D, Brown JS, Vittinghoff E et al (2001) Postmenopausal hormones and incontinence: the heart and estrogen/progestin replacement study. Obstet Gynecol 97:116–120CrossRefPubMed
24.
Andersson K-E, Appell R, Awad S et al (2002) Pharmacological treatment of urinary incontinence. In: Abrams P, Khoury S, Wein A (eds) Incontinence. Health Publications, Plymouth, pp 481–511
25.
Andersson KE (1988) Current concepts in the treatment of disorders of micturition. Drugs 35:477–494CrossRefPubMed
26.
Wein AJ (1995) Pharmacology of incontinence. Urol Clin N Am 22:557–577
27.
28.
Collste L, Lindskog M (1987) Phenylpropanolamine in treatment of female stress urinary incontinence. Double-blind placebo controlled study in 24 patients. Urology 40:398–403CrossRef
29.
Andersson KE, Appell R, Cardozo L (1999) The pharmacological treatment of urinary incontinence. BJU Int 84:923–947CrossRefPubMed
30.
Kerman WN, Viscoli CM, Brass LM et al (2000) Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343:1826–1832CrossRef
31.
Musselman DM, Ford AP, Gennevois DJ et al (2004) A randomized crossover study to evaluate Ro115–1240, a selective alpha1A/1 L adrenoceptor partial agonist in women with stress urinary incontinence. BJU Int 93:78–83CrossRefPubMed
32.
Wein AJ (2004) A randomized crossover study to evaluate Ro 115–1240, a selective alpha1A/1 L adrenoceptor partial agonist in women with stress urinary incontinence [editorial comment]. BJU Int 93:1115PubMed
33.
Weil EH, Eerdmans PH, Dijkman GA et al (1998) Randomized double- blind placebo-controlled multicenter evaluation of efficacy and dose finding of midodrine hydrochloride in women with mild to moderate stress urinary incontinence: a phase II study. Int Urogynecol J 9:145–150CrossRef
34.
Gleason DM, Reilly RJ, Bottacini MR et al (1974) The urethral continence zone and its relation to stress incontinence. J Urol 112:81–88PubMed
35.
Barlett DM, Wein AJ (1991) Voiding dysfunction: diagnosis, classification and management. In: Gillenwater JY, Grayhack JT, Howards ST, Duckett JW (eds) Adult and pediatric urology, 2nd edn. Mosby Year Book, St. Louis, pp 1001–1099
36.
Scarpero HM (2007) Pharmacological therapy for stress urinary incontinence. In: Goldman HB, Vasavada SP (eds) Female urology : a practical clinical guide. Humana Press, Totowa, p 89
37.
Viktrup L, Bump RC (2003) Pharmacological agents used for the treatment of stress urinary incontinence in women. Curr Med Res Opin 19:485–490CrossRefPubMed
38.
Ishiko O, Ushiroyama T, Saji F et al (2000) Beta(2)-adrenergic agonists and pelvic floor exercises for female stress incontinence. Int J Gynaecol Obstet 71:39–44CrossRefPubMed
39.
Yasuda K, Kawabe K, Takimoto Y et al (1993) A double-blind clinical trial of alpha2-adrenergic agonist in stress incontinence. Int Urogynecol J 4:146–151CrossRef
40.
Khullar V, Digesu A, Chaliha C et al (2002) “Mixed incontinence: how should it be treated?”. Neurourol Urodyn 21(4):378–379
41.
Thor KB (2002) Exploring new horizons in neurourology. Contemp Urol (Suppl):9–13
42.
Susie O, Ian R (2005) Duloxetine: the long awaited drug treatment for stress urinary incontinence. Obstet Gynecol 7:117–119CrossRef
43.
Norton P, Zinner NR, Yalcin I et al (2002) Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 187:40–48CrossRefPubMed
44.
Zinner N, Dmochowski R, Miklos J et al (2002) Duloxetine versus placebo in the treatment of stress urinary incontinence (SUI). Neurourol Urodyn 21:383–384
45.
Shah SM, Gaunay GS (2012) Treatment options for intrinsic sphincter deficiency. Nat Rev Urol 9:638–651PubMed
46.
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871–880CrossRefPubMed
47.
Thor KB, Katofiasc MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 274:1014–1024PubMed
48.
Dmochowski RR, Miklos JR, Norton PA et al (2003) Duloxetine versus placebo for the treatment of north American women with stress urinary incontinence. J Urol 170:1259–1263CrossRefPubMed
49.
Millard RJ, Moore K, Rencken R et al (2004) “Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial”. BJU Int 93:311–318CrossRefPubMed
50.
Van Kerrebroeck P, Abrams P, Lange R et al (2004) Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BJOG 111:249–257CrossRefPubMed
51.
Ghoniem GM, Van Leeuwen JS, Elser DM et al (2005) A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173:1647–1653CrossRefPubMed
52.
Katofiasc MA, Nissen J, Audia JE et al (2002) Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci 71:1227–1236CrossRefPubMed
53.
54.
Choi KT (2008) Botanical characteristics, pharmacological effects and medicinal components of Korean Panax ginseng C A Meyer. Acta Pharmacol Sin 29:1109–1118CrossRefPubMed
55.
Shergis JL, Zhang AL et al (2013) Quality and risk of bias in Panax ginseng randomized controlled trials: a review. Am J Chin Med 41:231–252CrossRefPubMed
56.
Guo XX, Guo Q et al (2012) Ginsenoside rh2 induces human hepatoma cell apoptosis via bax/bak triggered cytochrome C release and caspase-9/caspase-8 activation. Int J Mol Sci 13:15523–15535CrossRefPubMedCentralPubMed
57.
Chen YH, Lin YN, Chen WC et al (2014) Treatment of stress urinary incontinence by ginsenoside Rh2. Am J Chin Med 42(4):817–831CrossRefPubMed
Metadaten
Titel
Pharmacological treatment of pure stress urinary incontinence: a narrative review
verfasst von
Mariam A. Malallah
Tariq F. Al-Shaiji
Publikationsdatum
01.04.2015
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 4/2015
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-014-2512-9

Weitere Artikel der Ausgabe 4/2015

International Urogynecology Journal 4/2015 Zur Ausgabe

Letter to the Editor

Vaginal hysterectomy and training: response to Melendez

Original Article

Anal sphincter complex: 2D and 3D endoanal and translabial ultrasound measurement variation in normal postpartum measurements

Original Article

Influence of body mass index on the biomechanical properties of the human prolapsed anterior vaginal wall

Case Report

Pelvic organ prolapse in the neonate: report of two cases and review of the literature

Original Article

Perineorrhaphy quantitative assessment (Pe-QA)

Original Article

Low-cost transobturator vaginal tape inside-out procedure for the treatment of female stress urinary incontinence using ordinary polypropylene mesh

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen
Bildnachweise